Markus Goebel
Seasoned life science executive with deep expertise in innovation, corporate strategy and investments. Corporate Development Biotech& Medtech consulting. Director at public and private companies.
Switzerland
Invests in
Education
Lists including Markus
Investments
Work Experience
2024
Director
2024
OSE Immunotherapeutics is an integrated biotechnology company dedicated to developing First-In-Class Immunotherapies in Immuno-Inflammation (I&I) and Immuno-Oncology (I-O).
2022
Expert
2022
2022
Director
2022
hemotune AG is a pioneering Swiss biotech company based on nanoengineered magnetic beads and its breakthrough technology platform with multiple application possibilities. It has recently closed a CHF 14m Series B to advance the lead program into the clinic.
Founder & CEO
2019
Biotech and MedTech consulting
2020 - 2020
Director
2020 - 2020
HAYA Therapeutics is a Swiss-based pre-clinical early stage biopharmaceutical company dedicated to treating fibrotic diseases through the discovery and development of innovative targeted first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
2004 - 2019
Managing Director
2004 - 2019
• Managing Director Novartis Venture Fund (NVF) 2004-2019 (US & EU) • Investments: Sirtris (sirtuins), FoldRx (protein misfolding), Locus (in-silico drug design), Trellis (human MAbs), LigoCyte (vaccines), Visiogen (IOL device; co-lead), Ra Pharma (cyclic peptides), Sorbent (polymer for CHF), Intellikine (PI3K/mTOR pathway), Avila (covalent sm; co-lead), eFFECTOR (protein translation), merganser (hepcidin mimetics), AlloCyte (LFA-1 inhibitors), Expansion (repeat mRNA; co-lead), Ribon (monoPARPs) • Key investment contributions: Ablation Frontiers (AF device), Proteostasis (protein networks), Sonitus (hearing device) • Exits: IPO: Sirtris, Proteostasis, Ra Pharma; M&A: FoldRx (Pfizer), Ablation Frontiers (Medtronic), Visiogen (Abbott), Intellikine (Takeda), Avila (Celgene), LigoCyte (Takeda)
2000 - 2004
Head Pharma Corporate M&A
2002 - 2004
Acquisitions and divestments in and out of Novartis AG
Head Nervous System BD&L Pharma
2000 - 2002
Licensing options for Novartis Pharma in Nervous System
1992 - 1999
Several Marketing & Strategy positions incl. an alliance with Amgen
1992 - 1999
Head of Strategic Portfolio Management & Life Cycle Planning Pharma Senior Business Analyst Strategic Unit Pharma International Medical & Registration Manager Neupogen® (in co-operation with AMGEN)
1990 - 1992
Medical Manager Oncology & Medical Science
1990 - 1992